Form 4: NeuroOne Medical Technologies COO Acquires Options to Purchase 575,000 Shares

Christopher Volker, COO of NeuroOne Medical Technologies, acquired options to purchase 575,000 shares of common stock at an exercise price of $0.5796 on April 17, 2025.

Summary

• On April 17, 2025, Christopher Volker, the Chief Operating Officer of NeuroOne Medical Technologies Corp, was granted options to purchase 575,000 shares of the company's common stock.
• The exercise price for these options is $0.5796 per share.
• The options vest over time, with 25% vesting on April 17, 2026, and the remaining 75% vesting in 12 equal quarterly installments.
• The options expire on April 16, 2035.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a routine executive compensation disclosure.

Industry Context

This is a standard practice for compensating executives in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Granting stock options to executives is a common practice in the medical technology industry.
• Vesting schedules and exercise prices are typically determined based on company performance and industry benchmarks.
• Comparable companies like Medtronic or Boston Scientific also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The granting of stock options can incentivize management to improve company performance, potentially benefiting shareholders.
• Employees may view this as a positive sign of investment in leadership.

Key Dates

Keywords

NeuroOne Medical Technologies, NMTC, Christopher Volker, stock options, Form 4, insider trading, executive compensation, vesting schedule